Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Teva
Deloitte
Cantor Fitzgerald
Covington
Accenture
Johnson and Johnson
US Army
Farmers Insurance
Daiichi Sankyo

Generated: January 19, 2018

DrugPatentWatch Database Preview

Genzyme Company Profile

« Back to Dashboard

Summary for Genzyme
International Patents:276
US Patents:12
Tradenames:12
Ingredients:12
NDAs:15

Drugs and US Patents for Genzyme

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-003 Jul 13, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme CEREDASE alglucerase INJECTABLE;INJECTION 020057-004 May 8, 1992 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Genzyme

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-001 Jun 9, 1999 ➤ Subscribe ➤ Subscribe
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-002 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Genzyme THYROGEN thyrotropin alfa INJECTABLE;INJECTION 020898-001 Nov 30, 1998 ➤ Subscribe ➤ Subscribe
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-001 Jun 9, 1999 ➤ Subscribe ➤ Subscribe
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 ➤ Subscribe ➤ Subscribe
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-001 Apr 6, 2000 ➤ Subscribe ➤ Subscribe
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Subscribe ➤ Subscribe
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Subscribe ➤ Subscribe
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Subscribe ➤ Subscribe
Genzyme RENAGEL sevelamer hydrochloride TABLET;ORAL 021179-002 Jul 12, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GENZYME drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 24 mg/1.2 mL vials (20 mg/mL) ➤ Subscribe 12/17/2012
➤ Subscribe Injection 1 mg/mL, 20 mL vial ➤ Subscribe 2/23/2012
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 12/28/2011
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2/12/2010
➤ Subscribe Powder for Oral Suspension 0.8 g/packet and 2.4 g/packet ➤ Subscribe 12/30/2009
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 3/25/2009
➤ Subscribe Tablets 800 mg ➤ Subscribe 12/4/2008
➤ Subscribe Tablets 400 mg and 800 mg ➤ Subscribe 5/22/2008
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 10/15/2007

Non-Orange Book US Patents for Genzyme

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use ➤ Subscribe
6,255,336 Amino ceramide-like compounds and therapeutic methods of use ➤ Subscribe
7,763,738 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors ➤ Subscribe
5,034,518 2-fluoro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl) adenine nucleosides ➤ Subscribe
9,546,161 Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors ➤ Subscribe
8,138,353 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors ➤ Subscribe
6,030,995 Amino ceramide-like compounds and therapeutic methods of use ➤ Subscribe
7,169,750 Methods to mobilize progenitor/stem cells ➤ Subscribe
7,253,185 Amino ceramide-like compounds and therapeutic methods of use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Genzyme Drugs

Supplementary Protection Certificates for Genzyme Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90028-8 Sweden ➤ Subscribe PRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217
0150027 00161 Estonia ➤ Subscribe PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
00738 Netherlands ➤ Subscribe PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119
/2015 Austria ➤ Subscribe PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
/2009 Austria ➤ Subscribe PRODUCT NAME: SEVELAMERCARBONAT; REGISTRATION NO/DATE: EU/1/09/521/001- EU/1/09/521/007 20090610
033 Luxembourg ➤ Subscribe 92033, EXPIRES: 20240731
0543 Netherlands ➤ Subscribe PRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
2012 00026 Denmark ➤ Subscribe
2012011,C1411918 Lithuania ➤ Subscribe PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
C/GB06/040 United Kingdom ➤ Subscribe PRODUCT NAME: THE USE OF CLOFARABINE (2-CHLORO-9-(2-DEOXY-2-FLUORO-SS-D-ARABINOFURANOSYL)-ADENINE) FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER; REGISTERED: UK EU/1/06/334/001 20060529; UK EU/1/06/334/002 20060529; UK EU/1/06/334/003 20060529; UK EU/1/06/334/004 20060529
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
UBS
Cantor Fitzgerald
QuintilesIMS
Boehringer Ingelheim
Express Scripts
Deloitte
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot